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Abstract As the second most frequent neurodegenerative
disorder of the aging population, Parkinson’s disease (PD) is
characterized by progressive deficits in spontaneous move-
ment, atrophy of dopaminergic midbrain neurons and aggre-
gation of the protein alpha-synuclein (SNCA). To elucidate
molecular events before irreversible cell death, we studied
synucleinopathy-induced expression changes in mouse brain
and identified 49 midbrain/brainstem-specific transcriptional
dysregulations. In particular complexin-1 (Cplx1),Rabl2a and
14-3-3epsilon (Ywhae) downregulation, as well as upregula-
tion of the midbrain-specific factor forkhead box P1 (Foxp1)
and of Rabgef1, were interesting as early mRNA level effects
of alpha-synuclein triggered pathology. The protein levels of
complexin-1 were elevated in midbrain/brainstem tissue of
mice with A53T-SNCA overexpression and of mice with
SNCA-knockout. The response of CPLX1 and Foxp1 levels
to SNCA deficiency supports the notion that these factors are
regulated by altered physiological function of alpha-sy-
nuclein. Thus, their analysis might be useful in PD
stages before the advent of Lewy pathology. Because
both alpha-synuclein and complexin-1 modulate vesicle
release, our findings support presynaptic dysfunction as
an early event in PD pathology.
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Introduction
Parkinson’s disease (PD) is the second most frequent age-
associated brain degeneration disorder, affecting about 1 %
of the population over 65 years of age. The PD-specific
progressive movement deficit is mostly due to the severe
affliction and cell death of midbrain nigrostriatal dopaminer-
gic neurons [1]. Surviving neurons in vulnerable regions
exhibit aggregates predominantly consisting of the protein
alpha-synuclein, which are visualized as Lewy neurites and
Lewy bodies, both in sporadic late-onset and most familial
early onset PD variants [2].
Autosomal dominant PD with early clinical manifestation
was observed in rare families, leading to the identification of
alpha-synuclein (SNCA) protein missense mutations such as
A53T (termed the PARK1 variant) and of SNCA gene
duplication/triplication events (PARK4 variant) as the stron-
gest causes of this pathology [3, 4]. Further recruitment of
Parkinson’s families enabled identification of a list of
disease genes responsible for monogenic PD [5]. In
addition, recent characterization of very large collectives
of late-manifesting sporadic PD cases through genome-
wide allele association studies (GWAS) identified two
regions on chromosome 4 (SNCA and GAK/CPLX1 loci)
that contain genetic variants predisposing to multifacto-
rial PD [6]. Variations in the SNCA gene 3′-untranslated
region (3′-UTR) and its promoter correlated strongly
with PD risk [7].
Αlpha-synuclein is physiologically concentrated in axon
terminals. It is associated with the lipid membranes of synap-
tic vesicles and interacts with synaptobrevin, a component of
the SNARE complex, mediating vesicle exocytosis and neu-
rotransmitter release [8]. Its toxic gain-of-function leads over
time to impaired synaptic vesicle release and synaptic failure
[9, 10]. Current investigations aim to elucidate alpha-
synuclein-triggered pathology, concentrating on disease
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stages before the occurrence of irreversible cell loss, when
neuroprotective therapies might still be efficacious.
Here, we focused on two independent mouse lines of
inbred FVB/N background with ~1.5-fold overexpression of
human A53T-alpha-synuclein in nigrostriatal dopaminergic
neurons under control of the heterologous neuron-specific
prion-promoter. A53T-alpha-synuclein overexpression in the-
se mice occurs in presynaptic nigral dopaminergic neurons
and presynaptic cortical glutamatergic neurons, but not in
postsynaptic striatal neurons. These mice display apparently
normal movements at age 6 months, but progress to signifi-
cantly impaired spontaneous locomotion by age 18 months,
despite the absence of neuronal loss in the nigrostriatal pro-
jection [11]. Previous expression profiling in these mice iden-
tified a Homer-1a transcript dysregulation throughout the
brain and a 14-3-3 epsilon protein upregulation selectively in
the striatum as molecular effects of alpha-synuclein triggered
pathology. The alterations in these signalling molecules were
temporally correlated with reduced striatal dopamine release
and deficient long-term depression [12–14, 9]. To gain insight
into the mechanisms underlying the impairment in vesicle
exocytosis and neurotransmitter release, we surveyed progres-
sive expression changes in midbrain/brainstem tissue using
genome-wide unbiased transcriptome profiling. Promising
candidates were validated with quantitative immunoblots.
Results
Overexpression of A53T-Alpha-Synuclein Modulates Foxp1,
Cplx1, Rabl2a, Rabgef1 and Ywhae mRNA Levels in Mouse
Midbrain/Brainstem
Previously documented (GEO database GSE20547, see also
[12]) global transcriptome data from striatum, midbrain/
brainstem and cerebellum of human A53T-alpha-synuclein
overexpressing mice were filtered. We selected those signifi-
cant changes at age 18 months relative to age 6 months, which
were midbrain/brainstem-specific and were consistent be-
tween both transgenic mouse lines (PrPmtA and PrPmtB).
Further selection prioritized those transcripts with no corre-
sponding significant changes in wild-type midbrain/brainstem
and in wild-type/transgenic striatum and cerebellum, resulting
in the identification of 49 candidate effects of synucleinopathy
(Table 1). Among the progressive upregulation effects, the
increase of Foxp1 mRNA levels by A53T-alpha-synuclein
overexpression was particularly interesting in view of our
previous finding that Foxp1 (encoding forkhead box P1) is
downregulated in alpha-synuclein knockout mouse [15].
Thus, the midbrain-identity-mediating transcription factor
Foxp1 appears to depend in its brain levels both on the gain-
of-function and the loss-of-function of alpha-synuclein.
Among the progressive downregulation effects, the decreased
levels of Cplx1 (encoding complexin-1) selectively in the
mutant midbrain/brainstem were especially interesting, in
view of the co-localization of alpha-synuclein and
complexin-1 at the SNARE complex. Other midbrain/
brainstem-selective significant dysregulations of vesicle
endocytosis/exocytosis pathway factors included the down-
regulation of Rabl2a transcript and the upregulation of
Rabgef1, in good agreement with previous observations that
alpha-synuclein disrupts cellular Rab homeostasis [16]. More
ubiquitous dysregulations were detectable for three 14-3-3
isoforms (Table 1 bottom), which are established downstream
targets of alpha-synuclein function. 14-3-3 family isoforms
heterodimerize to protect phosphoserine-phosphothreonine
groups and are (1) sequence homologous to alpha-synuclein,
(2) putative direct interactor proteins of alpha-synuclein, (3)
expression-modulated by alpha-synuclein, (4) sequestered in-
to the Lewy bodies, (5) able to change their levels in response
to pathogenic alpha-synuclein mutations and thereby modu-
late neurotoxicity [17–20]. Thus, at least seven of the expres-
sion changes are credible in the light of their function and of
previous knowledge about alpha-synuclein. All information
per animal including age and sex with the resulting microarray
data discussed in this publication is deposited in the NCBI's
database Gene Expression Omnibus (GEO) and is accessible
through GEO series accession number GSE20547. Validation
studies of Cplx1 mRNA expression in independent tissues by
qPCR confirmed the significant downregulation in midbrain/
brainstem of PrPmtA mice (Fig. 1).
Overexpression of A53T-Alpha-Synuclein Leads to Elevated
Complexin-1 Protein Levels in Mouse Midbrain/Brainstem
We focused on the downregulation of midbrain/brainstem
Cplx1 mRNA as a novel and promising effect, since the
encoded protein complexin-1 is involved in the stimulus-
dependent control of secretory vesicle exocytosis through
the SNARE complex [21, 22]. Alpha-synuclein was also
shown to modulate SNARE assembly and vesicle clustering,
so this expression effect might constitute a very direct and
early consequence of alpha-synuclein mutations. Densitomet-
ric analysis of immunoblots revealed a significant increase of
complexin-1 protein levels in the midbrain/brainstem of aged
A53T-alpha-synuclein overexpressing mice (Fig. 2a–c), de-
spite Cplx1 mRNA downregulation. The alterations were
readily apparent by ECL detection of membranes, making
more sophisticated approaches such as near-infrared immuno-
blot detection or quantification by ELISA unnecessary.
Deficiency of Alpha-Synuclein Also Modulates
the Complexin-1 Levels in Mouse Midbrain/Brainstem
These data obtained in A53T-alpha-synuclein overexpressing
midbrain/brainstem complement previous observations from
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Table 1 Global transcriptome analysis of mice with nigrostriatal overexpression of human A53T-alpha-synuclein showing significant changes from age
6 to 18+months
1449674_s_at 0,778 0,787 0.030 0 0 0 0 −1 −1 0 0 0 Pdcd6ip 
synonymous ALIX, synonymous dopamine interacting protein 4, synonymous AIP1, cooperates with 
downregulated Chmp4 to trigger neuronal death (Mahul-Mellier-AL 2006 J Neurosci, Trioulier-Y 2004 J Biol 
Chem), increases D1 levels (Zhan-L 2008 Eur J Neurosci), activates caspase-9 and apoptosis in 
dependence on calcium (Vito-P 1999 J Biol Chem), controls exosome formation (Baietti-MF 2012 Nat Cell 
Biol) 
421142_s_at 1,809 2,001 0.030 0 0 0 0 1 1 0 0 0 Foxp1 
Promotes midbrain identity in embryonic stem cell derived dopamine neurons by regulating Pitx3 
(Konstantoulas-CJ 2010 J Neurochem, Xi-Y 2012 Stem Cells) 
1448297_a_at 0,663 0,677 0.031 0 0 0 0 −1 −1 0 0 0 Tnk2  
Synonymous ACK1, in endocytosis downstream of CDC2, preserves receptor membrane levels (Howlin-J 
2008 Breast Cancer Res), involved in synaptic plasticity, ACK1 containing clathrin-coated vesicles 
associate with SNX9 to contact synaptojanin (Yeow-Fong-L 2005 FEBS Lett, Teo-M 2001 J Biol Chem), 
localized pre- and postsynaptically (Ureña-JM 2005 J Comp Neurol) 
1434092_at 1,653 1,744 0.032 0 0 0 0 1 1 0 0 0 Nos3as 
Induced by hypoxia, inhibits endothelial NOS, essential for autophagosome formation (Yamada-T 2005 J 
Biol Chem, Fish-JE 2007 J Biol Chem) 
1446787_at 0,645 0,736 0.032 0 0 0 0 −1 −1 0 0 0 Commd1 
Synonymous MURR1, regulator of copper homeostasis, Na uptake (Ke-Y 2010 Am J Physiol Renal 
Physiol) and NF-kappa-B subunit RELA, binds XIAP as ubiquitin ligase (Maine-GN 2009 Biochem J) 
1417789_at 1,213 1,334 0.034 0 0 0 0 1 1 0 0 0 Ccl11 displays chemotactic activity, influence on dendritic branching (Foster-EL 2011 PLOS ONE) 
1416053_at 0,706 0,717 0.034 0 0 0 0 −1 −1 0 0 0 Lrrn1 adhesion protein, defines midbrain identity versus hindbrain (Tossell-K 2011 Dev Biol)  
1437125_at 1,897 2,233 0.034 0 0 0 0 1 1 0 0 0 Camk2a 
KO leads to reduced amphetamine-triggered DopamineTransporter-mediated MPP+ efflux (Steinkellner-T 
2012 J Biol Chem), substantia nigra expresses alpha rather than beta (Occhiishi-T 1998 Brain Res) 
1435043_at 0,734 0,809 0.037 0 0 0 0 −1 −1 0 0 0 Plcb1 
Protein levels are increased by alpha-synuclein binding (Guo-Y 2012 Cell Signal), in KO the synapse and 
spine morphology is altered (Spires-TL 2005 Cereb Cortex), in presence of Ca2+ catalyzes inositol 1,4,5-
trisphosphate and diacylglycerol formation, group I mGluRs are positively coupled to it (Rodríguez-A 2005 
Neuroscience)  
1444009_at 0,611 0,590 0.040 0 0 0 0 −1 −1 0 0 0 Rassf4 Induces Ras dependent apoptosis (Eckfeld-K 2004 Cancer Res) 
1434518_at 0,763 0,769 0.042 0 0 0 0 −1 −1 0 0 0 Phka2 glycogen breakdown activation 
1438033_at 0,621 0,682 0.042 0 0 0 0 −1 −1 0 0 0 Tef confers calcium responsiveness to ICER promoter (Krueger-DA 2000 J Biol Chem) 
1438821_at 0,663 0,688 0.042 0 0 0 0 −1 −1 0 0 0 Rfwd2 E3 ligase ubiquitinating Jun and 14-3-3, enhancing survival 
1452957_at 1,303 1,296 0.042 0 0 0 0 1 1 0 0 0 Krtap3-3 high sulfur KAP intermediate filament 
1418476_at 1,244 1,375 0.043 0 0 0 0 1 1 0 0 0 Crlf1 
induced by cocaine (Lattanzio-FA Jr 2005 Cardiovasc Toxicol), ligand for ciliary neurotrophic factor 
receptor (Rousseau-F 2006 PNAS) 
1440841_at 0,398 0,465 0.000 0 0 0 −1 −1 −1 0 0 −1 Ywhae 
14-3-3 epsilon, sequence homolog of alpha-synuclein (Ostrerova-N 1999 J Neurosci), interactor of 
alpha-synuclein (Xu-J 2002 Nat Med), protector of phospho-serine/phospho-threonine binding 
groups 
1457173_at 0,590 0,574 0.000 0 0 0 −1 −1 −1 −1 0 −1 Ywhae 
1416004_at 1,275 1,329 0.005 0 0 0 0 1 1 0 1 0 Ywhah 
14-3-3 eta, sequence homolog of alpha-synuclein (Ostrerova-N 1999 J Neurosci), interactor of alpha-
synuclein (Xu-J 2002 Nat Med), protector of phospho-serine/phospho-threonine binding groups 
1416004_at 1,275 1,329 0.005 0 0 0 0 1 1 0 1 0 Ywhah 
1448219_a_at 2,728 1,572 0.000 0 −1 −1 0 1 1 0 1 −1 Ywhaz 
14-3-3 zeta, protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), 
sequence homolog of alpha-synuclein (Ostrerova-N 1999 J Neurosci), interactor of alpha-synuclein (Xu-J 
2002 Nat Med), component of Lewy bodies (Berg-D 2003 Ann Neurol), protector of phospho-
serine/phospho-threonine binding groups  
lamellipodia/filopodia-forming RAC1/CDC42 pathway factors 
dopamine homeostasis factors 
endocytosis/exocytosis/exosome vesicle pathway factors 
peroxisomal-lysosomal degradation factors 
DNA damage factors 
hypoxia/oxidative stress factors 
known as alpha-synuclein modulated 
Affymetrix_ID RE_PrPmtA RE_PrPmtB adj.P.Value WT.S. A.S. B.S. WT.MB. A.MB. B.MB. WT.C. A.C. B.C. GeneSymbol Comments by GeneCards and PubMed databases
1432022_at 0,589 0,628 0.000 0 0 0 0 −1 −1 0 0 0 Cdgap 
Controls RAC1 and CDC42 for lamellipodia formation, interacts with Gab1 and intersectin, also (like 
downregulated DOCK6) mutated in Adams-Oliver syndrome type 1 with skin aplasia and brain 
abnormalities
1440531_at 1,990 1,610 0.000 0 0 0 0 1 1 0 0 0 Rbm11 Splice regulator antagonizing SRSF1 on Bcl transcript (Pedrotti-S 2012 Nucleic Acids Res)
1442056_at 0,375 0,512 0.003 0 0 0 0 −1 −1 0 0 0 Zfp608 Zink finger protein 
1450610_at 1,984 1,701 0.003 0 0 0 0 1 1 0 0 0 Ucn 
Stimulates the secretion of ACTH, simulates dopamine synthesis and modulates release (Bagosi-Z 2006 
Neurochem Res, Kim-Y 2009 Neurosci Lett), protective effect on 6OHDA- or MPTP-induced dopaminergic 
Neuron death (Abuirmeileh A 2009, Kim-Y 2010 Mol Cells)
1430850_x_at 1,576 1,280 0.006 0 0 0 0 1 1 0 0 0 Cgrrf1 RING finger domain, inhibiting growth of several cell lines 
1424700_at 1,410 1,401 0.006 0 0 0 0 1 1 0 0 0 Tmem38b Intracellular monovalent cation channel that functions in maintenance of rapid calcium release 
1422183_a_at 1,848 1,416 0.006 0 0 0 0 1 1 0 0 0 Adra1b
Facilitates dopamine transmission in the striatum and ventral midbrain (Rommelfanger-KS 2009   
Neuroscience, Velazquez-Martínez 2012 Neuroscience, Grenhoff-J 1995 Eur J Neurosci) 
1421164_a_at 0,651 0,605 0.009 0 0 0 0 0 0 0 Arhgef1 
Interacts with Rac1 in signal transduction, activates SRF-dependent transcription, its homologue Arhgef7 
(beta-pix) modulates actin-mediated recruitment of vesicles to synapses (Sun-Y 2011 J Neurosci) and is
implicated in synaptogenesis (Saneyoski-T 2008 Neuron) and is a target of NSF / SNAP (Martin-HG 2006 J 
Cell Biochem), Arhgef6 is a mental retardation protein 
1426240_at 0,653 0,757 0.009 0 0 0 0 -1 -1 0 0 0 Chmp4b
Functions in the sorting of endocytosed cell-surface receptors into multivesicular endosomes, together with
downregulated Pdcd6ip / Alix
1427735_a_at 1,783 1,474 0.009 0 0 0 0 1 1 0 0 0 Acta1 
Actin-alpha1, constituent of contractile apparatus, interactor of vesicles, associated with alpha-actinin, E-
cadherin and beta-catenin
1424256_at 1,533 1,421 0.010 0 0 0 0 1 1 0 0 0 Rdh12 KO attenuates neuritogenesis (Lin-Y 2012 FASEB J)
1418756_at 2,041 1,532 0.011 0 0 0 0 1 1 0 0 0 Trh 
Modulates 6OH-DA toxicity / behaviour (Andrews-JS 1985 Physiol Behav), transcript levels change after 
methamphetamine (Cadet-JL 2009 PLOS ONE)
1427240_at 0,734 0,729 0.013 0 0 0 0 0 0 0 Dock6 
Also (like downregulated Cdgap) mutated in Adams-Oliver syndrome with skin aplasia and brain 
abnormalities (Shaheen-R 2011 Am J Hum Genet)
1448832_a_at 0,779 0,859 0.014 0 0 0 0 0 0 0 Cplx1 
Protein levels increased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS)
fusion step of Ca-triggered exocytosis
1418250_at 1,723 1,461 0.015 0 0 0 0 1 1 0 0 0 Arfl4 May play a role in membrane-associated intracellular trafficking
1457198_at 0,502 0,637 0.016 0 0 0 0 0 0 0 Nrp1
part of receptor complex binding VEGF and semaphorins, upregulated by Nurr1 (Hermanson-E 2006 J 
Neurochem)
1436776_x_at 1,713 1,515 0.018 0 0 0 0 1 1 0 0 0 Slc7a4 arginine, lysine and ornithine transport 
1455599_at 0,744 0,828 0.018 0 0 0 0 0 0 0 Gfod1 contains glucose-fructose oxidoreductase domain
1455208_at 1,373 1,582 0.019 0 0 0 0 1 1 0 0 0 Pex19 cytosolic chaperone and as an import receptor for peroxisome membrane proteins
1442382_at 0,531 0,634 0.019 0 0 0 0 0 0 0 Mast4 PDZ domain, but expressed in oligondendrocytes 
1453267_at 0,548 0,561 0.020 0 0 0 0 0 0 0 Atbf1 
zinc finger transcription factor regulating neuronal differentiation, controls dopa-decarboxylase expression
and is found in dopaminergic neurons of substantia nigra (Ishii-Y 2003 J Comp Neurol), is induced by beta-
amyloid (Jung-CG 2011 Mol Neurodegener) 
1419495_at 1,544 1,440 0.020 0 0 0 0 1 1 0 0 0 Immp2l Downregulation increases ischemic brain damage (Ma-Y 2011 Neurobiol Dis)
1453072_at 1,380 1,591 0.020 0 0 0 0 1 1 0 0 0 Gpr160 orphan G-protein coupled receptor
1442782_at 0,673 0,714 0.020 0 0 0 0 0 0 0 Klhl8 
controls ubiquitin-degradation of rapsyn, which clusters nicotinic acetylcholine receptors in postsynapse 
(Nam-S 2009 J Biol Chem), release of dopamine in striatum of alpha-synuclein overexpressing mice is
modulated by acetylcholine (Platt-N 2012 PLOS ONE)
1459346_at 0,735 0,738 0.021 0 0 0 0 0 0 0 Tsen2 Mutated in pontocerebellar hypoplasia with extrapyramidal dyskinesia and chorea
1431931_a_at 0,662 0,675 0.022 0 0 0 0 0 0 0 Rabl2a important gene family for exocytosis and endocytosis 
1419440_at 1,397 1,374 0.023 0 0 0 0 1 1 0 0 0 Trim54 stabilizes microtubules
1452190_at 1,503 1,476 0.023 0 0 0 0 1 1 0 0 0 Prcp lysosomal enzyme induced by LPS 
1427401_at 1,749 1,698 0.023 0 0 0 0 1 1 0 0 0 Chrna5
expressed by dopaminergic SN neurons, agonists increase DA release in striatum (Clarke-PB 1996 Br J 
Pharmacol), increased after 6OHDA (Elliott-KJ J Mol Neurosci 1998) 
1419067_a_at 1,466 1,547 0.024 0 0 0 0 1 1 0 0 0 Rabgef1 Endocytic membrane trafficking, is a Abeta modifier gene (Rosenthal-SL 2012 Am J Neurodegen Dis) 
1451152_a_at 0,841 0,840 0.025 0 0 0 0 −1 −1 0 0 0 Atp1b1 beta subunit regulates the number of Na-pumps in plasma membrane
1424602_s_at 1,588 1,657 0.027 0 0 0 0 1 1 0 0 0 Xrcc4 
Efficient repair of DNA single-strand break, Xrcc1 polymorphisms associated with PD risk (Gencer-M 2012
Genet Test Mol Biomarkers, Cornetta-T 2013 Cell Mol Neurobiol) 
1436245_at 1,397 1,550 0.028 0 0 0 0 1 1 0 0 0 Usp20 Deubiquitination of beta-2 adrenergic receptor and HypoxiaInducedFactor1alpha










The upper rows show all 49 genes with known functions, which exhibited significant and consistent progression changes in both transgenic midbrain/
brainstem tissues, but not in wild-type midbrain/brainstem or striatum or cerebellum. Grey background with bold gene symbol and comments were used
to highlight the most promising novel expression effect of synucleinopathy, Cplx1 (encoding complexin-1). The lower rows show known expression
effects of synucleinopathy for comparison, highlighting the best previously established transcript Ywhae (encoding 14-3-3epsilon). Column (A)
documents the Affymetrix probeset ID; (B, C) the relative expression (RE) values for transgenic lines PrPmtA and PrPmtB, respectively, highlighting
changes >1.7 or <0.6 in bold letters; (D) the adjusted p value to judge significance after correction for multiple testing; (E–G) the lack of significant
changes (0) in striatum (S) of wild type (WT) and the two transgenic lines (A and B), respectively; (H–J) the lack of significant changes inWTcompared
to significant upregulations (1) or downregulations (−1) in midbrain/brainstem (MB) tissue of two transgenic lines A and B, respectively; (K–M) the lack
of significant changes in cerebellum (C) of wild type and two transgenic lines A and B, respectively; (N) the gene symbol to access GeneCards andNCBI
online databases using different background colours to emphasize functional pathways in common between individual genes; (O) authors’ summaries on
the functions of each gene product with respect to synaptic failure, according to GeneCards and PubMed online databases. The rows of the upper table
part were ordered from top in descending significance
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alpha-/beta-synuclein double-null mice, which exhibit upreg-
ulated complexin-1 and downregulated 14-3-3 epsilon protein
in the whole brain [23]. To test whether alpha-synuclein or
beta-synuclein is responsible for the observed changes, we
studied midbrain/brainstem from mice with Snca knockout in
129/SvEv background [24] and demonstrated significant up-
regulation for complexin-1 and downregulation for 14-3-
3epsilon protein (Fig. 2d–e). Thus, 14-3-3 isoform and
complexin-1 protein levels respond not only to toxic gain-
of-function mutations in alpha-synuclein but also to its loss-
of-physiological function.
Discussion
Our data confirm previous findings that alpha-synuclein abun-
dance modulates the levels of 14-3-3 isoforms. It was previ-
ously known that CPLX1 levels are altered in alpha + beta-
synuclein double-knockout mice and that Foxp1 mRNA
levels respond to the alpha-synuclein knockout. We now
report novel findings that also pathogenic gain-of-function
mutations of alpha-synuclein have a modulatory role on
CPLX1 and Foxp1 in mice that showed no demonstrable
alpha-synuclein aggregation in midbrain/brainstem during
their lifespan and that CPLX1 levels change in the alpha-
synuclein single knockout mouse brain.
This suggests that both CPLX1 and FOXP1 may be useful
to monitor early stages of alpha-synuclein pathology. FOXP1
is expressed preferentially in the midbrain. In contrast,
CPLX1 shows a more ubiquitous expression pattern, similar
to alpha-synuclein. Although both CPLX1 and SNCA were
mainly studied regarding presynaptic vesicle dynamics, their
expression in brain is not much higher than in blood platelets,
where they have a role in stimulus-dependent secretory vesicle
exocytosis to control thrombus formation [25]. Thus, CPLX1
might have potential as biomarker to monitor an alpha-
synuclein gain-of-function in peripheral tissues like blood.
Although our experiments were focused on modelling
monogenic alpha-synucleinopathy variants of PD (PARK4/
1), we are confident that complexin-1 plays a role in the
genetically heterogeneous common idiopathic PD. Our data
from alpha-synucleinopathy mouse models are consistent
with a proteome survey of midbrain from sporadic PD pa-
tients, which reported significantly elevated levels for
complexin-1 and a trend towards elevated levels of 14-3-3
epsilon [26]. Furthermore, theGAK/CPLX1 locus on chromo-
some 4 carries risk variants for sporadic PD in GWAS studies
[6].
The accumulation of CPLX1 in spite of reduced Cplx1
mRNA levels is intriguing. A plausible explanation might
predict that excess alpha-synuclein at the SNARE complex
interacts with CPLX1 and impairs its degradation. This could
occur as part of a sequestration process during the formation
of alpha-synuclein oligomers and aggregates, reflecting incip-
ient formation of inclusion bodies known as “Lewy neurites”
or “Lewy bodies”. It has been observed that this aggregation
process starts in the presynapses and sequesters local proteins
such as synapsin [27]. Overall, the transcriptomic profiling of
our PARK1/PARK4 mouse model identified plausible molec-
ular correlates of early nigrostriatal dopaminergic neurotrans-
mission deficits previously observed in this mouse [9].
In conclusion, the transcriptomic profiling of mouse
midbrain/brainstem tissue with alpha-synuclein pathology
has provided credible insights into early steps of pathogenesis,
before the advent of neurodegeneration. Complexin-1 may be
a better read-out of alpha-synucleinopathy than the previous
gold standard 14-3-3.
Materials and Methods
Ethics Statement Mice were housed in accordance with the
German Animal Welfare Act, the Council Directive of 24
November 1986 (86/609/EWG) with Annex II, the ETS123
(European Convention for the Protection of Vertebrate Ani-
mals) and the EU Directive 2010/63/EU for animal experi-
ments at the FELASA-certified Central Animal Facility (ZFE)
of the Frankfurt University Medical School.
Mouse breeding and characterizationwith brain dissection
was carried out as described in the literature [28, 29, 24]. All
studies of mouse mutants were in comparison with age- and
sex-matched WT controls from the same inbred background
line, which were bred and aged in parallel, under controlled
light cycle, periodic health-monitoring, and individually ven-
tilated cage housing. Dissection of brain regions occurred
Fig. 1 Quantitative real-time reverse transcriptase PCR demonstrates
reduced mRNA levels of complexin-1 in the midbrain/brainstem of mice
with A53T-alpha-synuclein overexpression. Tbp was always used as
loading control, and mRNA level ratios were normalized to WT. Asterisk
represents p value <0.05. Complexin-1 transcript was specifically detect-
ed by a custom-made Taqman assay, using midbrain/brainstem extracts
from the transgenic line PrPmtAversus wild type (WT) (n=18 versus 15)
at age 18 months, demonstrating a significant downregulation in PrPmtA
tissue
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Fig. 2 Quantitative immunoblots demonstrate dysregulated levels of
complexin-1 and 14-3-3epsilon proteins in the midbrain/brainstem of
mice with alpha-synuclein mutation. Beta-actin was always used as
loading control, and protein level ratios were normalized to WT. Repre-
sentative membranes are shown at the left, bar graph statistics of quan-
tification at the right. *p value <0.05, **p<0.01 and ***p<0.001. a
Complexin-1 and complexin-2 were detected with the antibody from
SySy, using midbrain/brainstem protein extracts from the transgenic line
PrPmtA versus wild type (WT) (n=3 versus 4) at age 18 months, dem-
onstrating significantly increased complexin-1 levels. b Midbrain/
brainstem protein from transgenic line PrPmtB versus wild type (WT)
(four vs. three) at age 18 months also showed significantly increased
complexin-1 levels. c In comparison, selective detection of 14-3-3epsilon
abundance change (five vs. five) as a repeatedly published molecular
effect of alpha-synucleinopathy failed to reveal changes in protein levels,
in spite of its significantly changed mRNA levels in mouse midbrain/
brainstem (Table 1). d Levels of complexin-1 and complexin-2 (antibody
from SySy) were significantly increased in alpha-synuclein knockout
mice (Snca KO) at age 3 months (five KO vs. four WT), in inverse
correlation to alpha-synuclein levels, demonstrating that complexin levels
respond not only to the toxic alpha-synuclein gain-of-function/aggrega-
tion process but also to its loss-of-function. e Significant downregulation
of 14-3-3epsilon (five KO vs. four WT). These data indicate that 14-3-
3epsilon protein levels are directly correlated to the loss-of-function of
alpha-synuclein
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rapidly after cervical dislocation, placing the brain in a sagittal
view to perform a coronal section from the hypophysis stem
towards the caudal end of the hippocampus. Olfactory brain
regions, the cerebral cortex, septal and thalamic tissue were
removed from the ventral tissue block to isolate the striatum.
To obtain midbrain/brainstem from the caudal tissue block,
the cortical, dorsal thalamic and tectal tissues were removed,
yielding the substantia nigra continuous with ventral tegmen-
tal area, red nucleus, mammillary nuclei and brainstem. For
the dissection of the cerebellum, its peduncles were cut at the
entry points into the hindbrain. All tissues were snap-frozen in
liquid nitrogen and then stored at −80 °C. Extraction of
protein and RNA was carried out as previously described
[30]. The individual transcript expression validation on a
StepOnePlus equipment (AppliedBiosystems) employed
TaqMan assays (AppliedBiosystems) Mm00447333_m1
(Snca), Mm01198853_m1 (Cplx1) and Mm00446973_m1
(Tbp), with quantitative real-time reverse transcriptase poly-
merase chain reaction (qPCR) conditions as recommended for
these assays.
Genome-wide transcriptomics of mouse brain regions was
performed with Affymetrix oligonucleotide microarrays as
previously reported [12].
Quantitative Immunoblots Frozen tissues were homogenized
on ice in a glass-Teflon douncer in RIPA buffer with 50 mm
Tris–HCl (pH 8), 150 mm NaCl, 1 % NP-40, 0.5 % Na-
deoxycholate, 0.1 % SDS and protease inhibitor cocktail
(Roche). Total lysates were briefly sonicated on ice, and cell
debris was removed by centrifugation. Protein concentration
was determined according to the method of Bradford. SDS–
PAGE-separated proteins (20 μg/lane) were blotted onto a
PVDFmembrane (Bio-Rad) and probed. The following primary
antibodies for mouse alpha-synuclein (1:1,000 BD Biosciences
610786), complexin-1 (1:500 Acris AP51050PU-N and 1:1,000
SySy 122002), 14-3-3epsilon/eta/zeta/beta/gamma/theta
(1:1,000 SantaCruz sc1020 and others from CellSignaling),
beta-actin (1:1,000 Sigma A5441) were used with their corre-
sponding secondary antibodies (GE Healthcare UK Limited
LNA931V/AG for ECL-anti-mouse-HP from sheep and
LNA934V/AG for ECL-anti-rabbit-HP from donkey) for 1 h.
The detection was made with SuperSignal West Pico (Thermo
Scientific), with varying exposure times to avoid film sensitivity
or saturation problems as well as non-linear effects. The images
were digitalized on a scanner (Epson) and densitometry per-
formed with the proprietary ImageMaster Total Lab 2.00 soft-
ware (AmershamPharmacia) or the public ImageJ software.
After normalization of candidate protein values versus beta-
actin values from the identical membrane in EXCEL, the chang-
es were evaluated in GraphPad statistics and plotting.
Statistical analyses presented in bar graphs were performed
by unpaired Student’s t tests and plotted with the Prism 3
software (GraphPad, La Jolla, CA, USA).
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